Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 2557

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Pharmaceuticals
  • HIV / AIDs
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2557

License Grant
The Licensee was granted exclusive, worldwide rights under the Licensed Patents and under the Licensed Technology to possess, use, make, have made, lease, sell and have sold all Materials, Progeny, Biomaterials, Technology, Improvements thereto, and Licensed Products.
License Property
Licensed Patents shall include U.S. Patent No. 5,484,735 to  Davis et al. filed November 12, 1993 and entitled Immunoassay of Glycosylated Proteins Employing Antibody to Reductive Glycosylated N-Terminal Amino Acids (hereinafter referred to as the 735 Patent).
Field of Use
Licensee desires to develop commercial diagnostic assays for determining hemoglobin in type Alc (Hb(Alc)) by detecting a reduced form of Hb(Alc).  Licensee desires to grow such cell lines and harvest monoclonal antibodies from said cell lines for the purpose of evaluating the suitability of the same for a commercial Hb(Alc) assay and for the purpose of evaluating whether to exercise an option to license the exclusive, worldwide rights associated with such cell lines, such monoclonal antibodies and such related information known to the Licensor.

IPSCIO Record ID: 1801

License Grant
The University grants to Licensee and its Affiliates an exclusive worldwide license under Patent Rights (5,484,735) relating to Immunoassay Constructs to Quantitate Glucosylated-Hemoglobin and other Glucosylated Serum Proteins (NU 8403).
License Property
'Licensed Products' shall mean diagnostic assays for determining hemoglobin type A1c.
Field of Use
'Field' shall mean the use of immunoassays for diagnostic purposes to quantitate hemoglobin type A1c.

IPSCIO Record ID: 4861

License Grant
The Licensee was granted the exclusive worldwide, right to a diagnostic assay useful for detecting lipoprotein (a), Lp; technical expertise to develop hybridoma cell lines that produce antibodies for use in such assay.
License Property
A lipoprotein is a biochemical assembly that contains both proteins and lipids, bound to the proteins, which allow fats to move through the water inside and outside cells.  Lipoproteins is any of a group of soluble proteins that combine with and transport fat or other lipids in the blood plasma.
Field of Use
The Licensee desires to grow such cell lines and harvest monoclonal antibodies from said cell lines and to make, use and sell products manufactured using such antibodies and desires to obtain the exclusive, worldwide rights to harvest such antibodies and make, use and sell such products.

IPSCIO Record ID: 25977

License Grant
The Canadian Licensor will grant the Licensee an exclusive sub-license option on technology to use the technology in Licensor's antibody improvement platforms. The technology grant will also include the non-exclusive use to make genetically engineered forms or humanized forms and to derive fully human antibodies.
Field of Use
Licensee will use best efforts to promptly commercialize the technology as permitted in this SubLicense.

IPSCIO Record ID: 4026

License Grant
The Licensor, an individual, hereby grants to the Licensee an exclusive License, within the worldwide territory, except Japan, to utilize the Technology to develop, manufacture, use, promote to sell, and sell any Products during the term of this License Agreement. The Licensee shall not subLicense such rights to any third parties without prior written consent of the Licensor.
License Property
The Licensor is willing to grant access to all information in his possession regarding methods for the determination of oxidized lipoproteins and access to all related analytes, antibodies and antigens, existing as of the date of this License Agreement and any and all improvements or future developments related thereto, including those related to the Patents or the Japanese Patents to develop any human diagnostic products to be manufactured and sold by Corgenix, including those that include the Patents or the Japanese Patents.

Licensed Patents:
5,900,359; 7,160,733; 7,422,864; 7,455,976; 1 548 436; 04713170
Japanese Patents: 07-510213; PCT/JP02/00723; 2002-261366

Field of Use
The exclusive rights granted relates to the methods to determine oxidized lipoproteins and related analytes, antibodies and antigens.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.